Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
The company asked the court to dismiss a negligence case involving St. Jude Medical's Riata ST lead, but a federal judge denied the motion, allowing the case to proceed.
Otsuka Holdings is set to acquire ReCor Medical for an undisclosed sum and follows Medtronic in a bid to get a renal denervation device on the market.
FDA gave ReCor Medical the green light to run a pivotal study of its ultrasound-based renal denervation system for the treatment of hypertension.
A Cleveland Clinic doctor talks about his hope for the future of better in-patient monitoring on the general care floors, and how an ongoing global trial using a Medtronic device could be a big step toward making that vision a reality.
Centers for Medicare & Medicaid Services opened a national coverage analysis to reconsider its 2012 coverage decision regarding transcatheter aortic valve replacement.
Cleveland Clinic physicians have completed a study that shows leadless pacemakers might be a safer option than traditional transvenous pacemakers.
Philips is set to pick up EPD Solutions, a company that specializes in image-guided procedures for cardiac arrhythmias, for about $292 million upfront, in a transaction set to be completed in July.
The private company said the first patient has been treated with its J-Valve TF System for aortic regurgitation.
The company is now gearing up for a larger more in-depth study that could put it on the path to get a nod from FDA.
Medtronic reported earning $8.14 billion in sales for its most recent quarter driven primarily by recent developments and product offerings from its diabetes and cardiovascular units.
If the Amplatzer Amulet Left Atrial Appendage (LAA) occlusion device gains approval in the U.S., the device could go head-to-head with Boston Scientific’s Watchman.
TAVR pioneer Edwards Lifesciences has released positive 30-day data of its Sapien 3 valve at EuroPCR.